Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy.
Journal article
Khalique H. et al, (2021), J Immunother Cancer, 9
External Beam Radiation Therapy and Enadenotucirev: Inhibition of the DDR and Mechanisms of Radiation-Mediated Virus Increase.
Journal article
Pokrovska TD. et al, (2020), Cancers (Basel), 12
The role of cancer metabolism in defining the success of oncolytic viro-immunotherapy
Journal article
Dyer A. et al, (2020), Cytokine and Growth Factor Reviews
Bi- and tri-valent T cell engagers deplete tumour-associated macrophages in cancer patient samples.
Journal article
Scott EM. et al, (2019), J Immunother Cancer, 7
Turning cold tumours hot: oncolytic virotherapy gets up close and personal with other therapeutics at the 11th Oncolytic Virus Conference.
Journal article
Dyer A. et al, (2019), Cancer Gene Ther, 26, 59 - 73
Antagonism of Glycolysis and Reductive Carboxylation of Glutamine Potentiates Activity of Oncolytic Adenoviruses in Cancer Cells.
Journal article
Dyer A. et al, (2019), Cancer Res, 79, 331 - 345
Group B adenovirus enadenotucirev infects polarised colorectal cancer cells efficiently from the basolateral surface expected to be encountered during intravenous delivery to treat disseminated cancer.
Journal article
Chia S-L. et al, (2017), Virology, 505, 162 - 171
Oncolytic Group B Adenovirus Enadenotucirev Mediates Non-apoptotic Cell Death with Membrane Disruption and Release of Inflammatory Mediators.
Journal article
Dyer A. et al, (2017), Mol Ther Oncolytics, 4, 18 - 30